Tags:BioTechCareDevelopmentDiagnosticsDrugPlatformResearchServiceTools
At Boreal, we are committed to improving cancer patient care through development of research tools and diagnostic tests based on monitoring of circulating tumor DNA in plasma. Boreal’s OnTarget™ platform performs highly sensitive mutation detection to enable accurate tumor profiling and real-time monitoring of tumor evolution from cell-free DNA in plasma. The OnTarget™ assay is available as a research-use service to reveal tumor mutations that are undetectable with other methods and may help guide selection of therapy, improve clinical trial efficiency, and accelerate drug development programs.
Location: Canada, British Columbia, Electoral Area A
Member count: 11-50
Total raised: $18M
Founded date: 2007

Investors 3

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
05.10.2013Series C$18M-finsmes.co...

Mentions in press and media 4

DateTitleDescriptionCategoryAuthorSource
25.06.2015Single-cel...Single-cell technologies advan...--cambridgen...
25.06.2015Single-cel...Biologists are looking to extr...--cambridgen...
07.10.2013Boreal Gen... LOS ALTOS, CA, Privately hel...--vcnewsdail...
05.10.2013Boreal Gen...Boreal Genomics, a Los Altos, ...funding S...-finsmes.co...